Now showing items 1-13 of 13

    • Anti-KIT designer T cells for the treatment of gastrointestinal stromal tumor 

      Katz, Steven C; Burga, Rachel A; Naheed, Seema; Licata, Lauren A; Thorn, Mitchell; Osgood, Doreen; Nguyen, Cang T; Espat, N Joseph; Fletcher, Jonathan A.; Junghans, Richard P (BioMed Central, 2013)
      Background: Imatinib mesylate is an effective treatment for metastatic gastrointestinal stromal tumor (GIST). However, most patients eventually develop resistance and there are few other treatment options. Immunotherapy ...
    • Comparative Gene Expression Profiling of Benign and Malignant Lesions Reveals Candidate Therapeutic Compounds for Leiomyosarcoma 

      Edris, Badreddin; Fletcher, Jonathan A.; West, Robert B.; van de Rijn, Matt; Beck, Andrew H. (Hindawi Publishing Corporation, 2012)
      Leiomyosarcoma (LMS) is a malignant, soft-tissue tumor for which few effective therapies exist. Previously, we showed that there are three molecular subtypes of LMS. Here, we analyzed genes differentially expressed in each ...
    • Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3 

      Yang, Peipei; Chen, Weicai; Li, Xuhui; Eilers, Grant; He, Quan; Liu, Lili; Wu, Yeqing; Wu, Yuehong; Yu, Wei; Fletcher, Jonathan A.; Ou, Wen-Bin (Impact Journals LLC, 2016)
      The MDM2-p53 pathway has a prominent oncogenic function in the pathogenesis of various cancers. Nutlin-3, a small-molecule antagonist of MDM2-p53 interaction, inhibits proliferation in cancer cells with wild-type p53. ...
    • Dystrophin Is a Tumor Suppressor in Human Cancers with Myogenic Programs 

      Wang, Yuexiang; Marino-Enriquez, Adrian; Bennett, Richard R.; Zhu, Meijun; Shen, Yiping; Eilers, Grant; Lee, Jen-Chieh; Henze, Joern; Fletcher, Benjamin S.; Gu, Zhizhan; Fox, Edward A.; Antonescu, Cristina R.; Fletcher, Christopher D.M.; Guo, Xiangqian; Raut, Chandrajit P.; Demetri, George D.; van de Rijn, Matt; Ordog, Tamas; Kunkel, Louis M.; Fletcher, Jonathan A. (2014)
      Many common human mesenchymal tumors, including gastrointestinal stromal tumor (GIST), rhabdomyosarcoma (RMS), and leiomyosarcoma (LMS), feature myogenic differentiation1–3. Here we report that intragenic deletion of the ...
    • Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors 

      Demetri, George Daniel; von Mehren, Margaret; Blanke, Charles D.; Van Den Abbeele, Annick Diane; Eisenberg, Burton; Roberts, Peter J.; Heinrich, Michael C.; Tuveson, David A.; Singer, Samuel; Janicek, Milos; Fletcher, Jonathan A.; Silverman, Stuart George; Silberman, Sandra L.; Capdeville, Renaud; Kiese, Beate; Peng, Bin; Dimitrijevic, Sasa; Druker, Brian J.; Corless, Christopher; Fletcher, Christopher D.M.; Joensuu, Heikki (New England Journal of Medicine (NEJM/MMS), 2002)
      Background Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical ...
    • HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status 

      Ou, Wen-Bin; Zhu, Jiaqing; Eilers, Grant; Li, Xuhui; Kuang, Ye; Liu, Li; Mariño-Enríquez, Adrián; Yan, Ziqin; Li, Hailong; Meng, Fanguo; Zhou, Haimeng; Sheng, Qing; Fletcher, Jonathan A. (Impact Journals LLC, 2015)
      The MDM2-p53 pathway plays a prominent role in well-differentiated liposarcoma (LPS) pathogenesis. Here, we explore the importance of MDM2 amplification and p53 mutation in LPS independently, to determine whether HDACi are ...
    • Inhibition of KIT-Glycosylation by 2-Deoxyglucose Abrogates KIT-Signaling and Combination with ABT-263 Synergistically Induces Apoptosis in Gastrointestinal Stromal Tumor 

      Mühlenberg, Thomas; Grunewald, Susanne; Treckmann, Jürgen; Podleska, Lars; Schuler, Martin; Fletcher, Jonathan A.; Bauer, Sebastian (Public Library of Science, 2015)
      Positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) is frequently used for visualizing gastrointestinal stromal tumors (GIST), which are highly glucose-avid tumors. Dramatic metabolic responses following ...
    • Membrane-To-Nucleus Signaling Links Insulin-Like Growth Factor-1- and Stem Cell Factor-Activated Pathways 

      Hayashi, Yujiro; Asuzu, David T.; Gibbons, Simon J.; Aarsvold, Kirsten H.; Bardsley, Michael R.; Lomberk, Gwen A.; Mathison, Angela J.; Kendrick, Michael L.; Shen, K. Robert; Taguchi, Takahiro; Gupta, Anu; Rubin, Brian P.; Fletcher, Jonathan A.; Farrugia, Gianrico; Urrutia, Raul A.; Ordog, Tamas (Public Library of Science, 2013)
      Stem cell factor (mouse: Kitl, human: KITLG) and insulin-like growth factor-1 (IGF1), acting via KIT and IGF1 receptor (IGF1R), respectively, are critical for the development and integrity of several tissues. Autocrine/paracrine ...
    • No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone 

      Peterse, Elisabeth F. P.; Cleven, Arjen H. G.; De Jong, Yvonne; Briaire-de Bruijn, Inge; Fletcher, Jonathan A.; Danen, Erik H. J.; Cleton-Jansen, Anne-Marie; Bovée, Judith V. M. G. (BioMed Central, 2016)
      Background: Chondrosarcoma is a malignant cartilage forming bone tumour for which no effective systemic treatment is available. Previous studies illustrate the need for a better understanding of the role of the IGF pathway ...
    • p53 Modulation as a Therapeutic Strategy in Gastrointestinal Stromal Tumors 

      Henze, Joern; Mühlenberg, Thomas; Simon, Susanne; Grabellus, Florian; Rubin, Brian; Taeger, Georg; Schuler, Martin; Treckmann, Juergen; Debiec-Rychter, Maria; Taguchi, Takahiro; Bauer, Sebastian; Fletcher, Jonathan A. (Public Library of Science, 2012)
      The KIT-inhibitor imatinib mesylate (IM) has greatly improved the treatment of metastatic gastrointestinal stromal tumors (GIST). IM exhibits strong antiproliferative effects but fails to induce sufficient levels of apoptosis ...
    • Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma 

      Nakayama, Robert; Zhang, Yi-Xiang; Czaplinski, Jeffrey T.; Anatone, Alex J.; Sicinska, Ewa T.; Fletcher, Jonathan A.; Demetri, George D.; Wagner, Andrew J. (Impact Journals LLC, 2016)
      Selinexor is an orally bioavailable selective inhibitor of nuclear export that has been demonstrated to have preclinical activity in various cancer types and that is currently in Phase I and II clinical trials for advanced ...
    • Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples 

      Campbell, Catarina D.; Kehoe, Sarah M.; Hatton, Charles; Niu, Lili; Yao, Keluo; Hanna, Megan; Mondal, Chandrani; Luongo, Lauren; Baker, Alissa C.; Philips, Juliet; Goff, Deborah J.; Rubin, Mark A.; Corso, Gianni; Roviello, Franco; MacConaill, Laura Eleanor; Bass, Adam Joel; Davis, Matthew J; Emery, Caroline Margaret; Fiorentino, Michelangelo; Polyak, Kornelia; Chan, Jennifer Ang; Wang, Yufang; Fletcher, Jonathan A.; Santagata, Sandro; Shivdasani, Ramesh Arjun; Kieran, Mark W.; Ligon, Keith Lloyd; Stiles, Charles Dean; Hahn, William C.; Meyerson, Matthew Langer; Garraway, Levi Alexander; Jones, Chris (Public Library of Science, 2009)
      Background: Detection of critical cancer gene mutations in clinical tumor specimens may predict patient outcomes and inform treatment options; however, high-throughput mutation profiling remains underdeveloped as a diagnostic ...
    • The Protein Kinase C Inhibitor Enzastaurin Exhibits Antitumor Activity against Uveal Melanoma 

      Wu, Xinqiang; Zhu, Meijun; Fletcher, Jonathan A.; Giobbie-Hurder, Anita; Hodi, Frank Stephen (Public Library of Science, 2012)
      GNAQ mutations at codon 209 have been recently identified in approximately 50% of uveal melanomas (UM) and are reported to be oncogenic through activating the MAPK/Erk1/2 pathway. Protein kinase C (PKC) is a component of ...